European Patent Office will grant a diagnostic CD73 patent for Faron
20120302.pdf (18.3 kt)
20120302.pdf (18.3 kt)
Virtual drug company
Cost effective innovation power »Synergistics technologies
Bodyguarding diseases at endothelial barriers »Drug candidates
Large indications with unmet medical needs »Recent news
Faron has initiated development of GMP manufacturing of the humanized anti-Clever-1 antibody FP-1304 with Biovian
20111012.pdf (48.0 kt)The FPCLI001 clinical trial with FP-1201 in acute lung injuries has been completed: also the long-term secondary end point demonstrates a significant decrease in mortality
20111007.pdf (39.6 kt)Faron reports positive headline data from FPCLI001 clinical study with FP- 1201 in acute lung injuries
20110509.pdf (47.7 kt)Faron is a virtual drug company focusing to discovery and development of proprietary new compounds/use for:
- vasculopathies
- traumas
- inflammation
- metastasis